中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

原发性胆汁性胆管炎合并脂质代谢异常的研究进展

袁诗雨 杨焕焕 唐映梅

引用本文:
Citation:

原发性胆汁性胆管炎合并脂质代谢异常的研究进展

DOI: 10.12449/JCH240125
基金项目: 

云南省医学领军人才项目 (L-2019013)

云南万人项目 (YNWR-MY-2018-028)

昆明医科大学第二附属医院临床研究项目 (2020ynlc010)

利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:袁诗雨负责起草文章,对行文的思路和设计有关键贡献;杨焕焕、唐映梅参与了修改文章关键内容。
详细信息
    通信作者:

    唐映梅, tangyingmei_med@kmmu.edu.cn (ORCID: 0000-0002-0731-4198)

Research advances in primary biliary cholangitis with dyslipidemia

Research funding: 

Medicine Leading Talents of Yunnan Province (L-2019013);

Yunnan Wanren Project (YNWR-MY-2018-028);

Clinical Research Project of the Second Affiliated Hospital of Kunming Medical University (2020ynlc010)

More Information
  • 摘要: 原发性胆汁性胆管炎(PBC)是一种以肝内中小胆管进行性、非化脓性炎症为特征的自身免疫性肝病。近期研究发现PBC患者中脂质代谢异常较为常见,76%的PBC患者常合并血脂异常,其作用及危害备受关注。脂质代谢紊乱在PBC发展中起重要作用,本文主要从脂质代谢紊乱在PBC中的表现及作用、诊断及治疗方面的研究进展展开综述,以期为PBC治疗提供新的思路。

     

  • [1] RESHETNYAK VI, MAEV IV. Features of lipid metabolism disorders in primary biliary cholangitis[J]. Biomedicines, 2022, 10( 12): 3046. DOI: 10.3390/biomedicines10123046.
    [2] ZENG N, DUAN WJ, CHEN S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: A systematic review and meta-analysis[J]. Hepatol Int, 2019, 13( 6): 788- 799. DOI: 10.1007/s12072-019-09984-x.
    [3] AHOUSSOUGBEMEY MELE A, MAHMOOD R, OGBUAGU H, et al. Hyperlipidemia in the setting of primary biliary cholangitis: A case report and review of management strategies[J]. Cureus, 2022, 14( 11): e31411. DOI: 10.7759/cureus.31411.
    [4] WAH-SUAREZ MI, DANFORD CJ, PATWARDHAN VR, et al. Hyperlipidaemia in primary biliary cholangitis: Treatment, safety and efficacy[J]. Frontline Gastroenterol, 2019, 10( 4): 401- 408. DOI: 10.1136/flgastro-2018-101124.
    [5] LOAEZA-DEL CASTILLO AM, GAYTÁN-SANTILLÁN A, LÓPEZ-TELLO A, et al. Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis[J]. Ann Hepatol, 2019, 18( 6): 879- 882. DOI: 10.1016/j.aohep.2019.07.006.
    [6] SEQUEIRA C, COELHO M, COSTA SANTOS I, et al. Severe Hypercholesterolemia mediated by lipoprotein X in an immunosuppressed patient: a case report[J]. GE Port J Gastroenterol, 2022, 30( 5): 398- 402. DOI: 10.1159/000526854.
    [7] FELLIN R, MANZATO E. Lipoprotein-X fifty years after its original discovery[J]. Nutr Metab Cardiovasc Dis, 2019, 29( 1): 4- 8. DOI: 10.1016/j.numecd.2018.09.006.
    [8] ZHANG Y, HU X, CHANG J, et al. The liver steatosis severity and lipid characteristics in primary biliary cholangitis[J]. BMC Gastroenterol, 2021, 21( 1): 395. DOI: 10.1186/s12876-021-01974-4.
    [9] KJELDSEN EW, NORDESTGAARD LT, FRIKKE-SCHMIDT R. HDL cholesterol and non-cardiovascular disease: A narrative review[J]. Int J Mol Sci, 2021, 22( 9): 4547. DOI: 10.3390/ijms22094547.
    [10] SARIN SK, KUMAR M, ESLAM M, et al. Liver diseases in the asia-pacific region: A lancet gastroenterology& hepatology commission[J]. Lancet Gastroenterol Hepatol, 2020, 5( 2): 167- 228. DOI: 10.1016/S2468-1253(19)30342-5.
    [11] LEMOINNE S, KEMGANG A, BELKACEM K BEN, et al. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis[J]. Gut, 2020, 69( 1): 92- 102. DOI: 10.1136/gutjnl-2018-317791.
    [12] FELLIN R, MANZATO E. Lipoprotein-X fifty years after its original discovery[J]. Nutr Metab Cardiovasc Dis, 2019, 29( 1): 4- 8. DOI: 10.1016/j.numecd.2018.09.006.
    [13] NEMES K, ABERG F, GYLLING H, et al. Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implications[J]. World J Hepatol, 2016, 8( 22): 924- 932. DOI: 10.4254/wjh.v8.i22.924.
    [14] HARRIS J, CAO S, HILE G, et al. Diffuse xanthomas in a patient with primary biliary cholangitis and lipoprotein X[J]. JAAD Case Rep, 2020, 7: 30- 32. DOI: 10.1016/j.jdcr.2020.10.029.
    [15] PAN XY, ZHANG ZM, LIU CQ, et al. Circulating levels of DDIT4 and mTOR, and contributions of BMI, inflammation and insulin sensitivity in hyperlipidemia[J]. Exp Ther Med, 2022, 24( 5): 666. DOI: 10.3892/etm.2022.11602.
    [16] MAHDAVI-ROSHAN M, SHOAIBINOBARIAN N, NOORMOHAMMADI M, et al. Inflammatory markers and atherogenic coefficient: Early markers of metabolic syndrome[J]. Int J Endocrinol Metab, 2022, 20( 4): e127445. DOI: 10.5812/ijem-127445.
    [17] SUN W, LI PC, CAI JP, et al. Lipid metabolism: Immune regulation and therapeutic prospectives in systemic lupus erythematosus[J]. Front Immunol, 2022, 13: 860586. DOI: 10.3389/fimmu.2022.860586.
    [18] SALAHUDDIN T, NATARAJAN B, PLAYFORD MP, et al. Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis[J]. Eur Heart J, 2015, 36( 39): 2662- 2665. DOI: 10.1093/eurheartj/ehv339.
    [19] WIDENMAIER SB, SNYDER NA, NGUYEN TB, et al. NRF1 is an ER membrane sensor that is central to cholesterol homeostasis[J]. Cell, 2017, 171( 5): 1094- 1109. e 15. DOI: 10.1016/j.cell.2017.10.003.
    [20] TALL AR, WESTERTERP M. Inflammasomes, neutrophil extracellular traps, and cholesterol[J]. J Lipid Res, 2019, 60( 4): 721- 727. DOI: 10.1194/jlr.S091280.
    [21] GILL PK, DRON JS, HEGELE RA. Genetics of hypertriglyceridemia and atherosclerosis[J]. Curr Opin Cardiol, 2021, 36( 3): 264- 271. DOI: 10.1097/HCO.0000000000000839.
    [22] ZHANG BH, YIN F, QIAO YN, et al. Triglyceride and triglyceride-rich lipoproteins in atherosclerosis[J]. Front Mol Biosci, 2022, 9: 909151. DOI: 10.3389/fmolb.2022.909151.
    [23] DEN HARTIGH LJ, ALTMAN R, NORMAN JE, et al. Postprandial VLDL lipolysis products increase monocyte adhesion and lipid droplet formation via activation of ERK2 and NFκB[J]. Am J Physiol Heart Circ Physiol, 2014, 306( 1): H109- H120. DOI: 10.1152/ajpheart.00137.2013.
    [24] LEE SH, KIM N, KIM M, et al. Single-cell transcriptomics reveal cellular diversity of aortic valve and the immunomodulation by PPARγ during hyperlipidemia[J]. Nat Commun, 2022, 13( 1): 5461. DOI: 10.1038/s41467-022-33202-2.
    [25] MANNE V, KOWDLEY KV. Obeticholic acid in primary biliary cholangitis: Where we stand[J]. Curr Opin Gastroenterol, 2019, 35( 3): 191- 196. DOI: 10.1097/MOG.0000000000000525.
    [26] LAZARIDIS KN, GORES GJ, LINDOR KD. Ursodeoxycholic acid‘mechanisms of action and clinical use in hepatobiliary disorders’[J]. J Hepatol, 2001, 35( 1): 134- 146. DOI: 10.1016/s0168-8278(01)00092-7.
    [27] NADINSKAIA M, MAEVSKAYA M, IVASHKIN V, et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2021, 27( 10): 959- 975. DOI: 10.3748/wjg.v27.i10.959.
    [28] MOUILLOT T, BEYLOT M, DRAI J, et al. Effect of bile acid supplementation on endogenous lipid synthesis in patients with short bowel syndrome: A pilot study[J]. Clin Nutr, 2020, 39( 3): 928- 934. DOI: 10.1016/j.clnu.2019.03.037.
    [29] HIRSCHFIELD GM, CHAZOUILLÈRES O, CORTEZ-PINTO H, et al. A consensus integrated care pathway for patients with primary biliary cholangitis: A guideline-based approach to clinical care of patients[J]. Expert Rev Gastroenterol Hepatol, 2021, 15( 8): 929- 939. DOI: 10.1080/17474124.2021.1945919.
    [30] PELLICCIARI R, FIORUCCI S, CAMAIONI E, et al. 6alpha-ethyl-chenodeoxycholic acid(6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity[J]. J Med Chem, 2002, 45( 17): 3569- 3572. DOI: 10.1021/jm025529g.
    [31] ROY PP, MAHTAB MA, RAHIM MA, et al. Treatment of nonalcoholic steatohepatitis by obeticholic acid: Current status[J]. Euroasian J Hepatogastroenterol, 2022, 12( Suppl 1): S46- S50. DOI: 10.5005/jp-journals-10018-1360.
    [32] NEVENS F, ANDREONE P, MAZZELLA G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med, 2016, 375( 7): 631- 643. DOI: 10.1056/NEJMoa1509840.
    [33] SAMUR S, KLEBANOFF M, BANKEN R, et al. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis[J]. Hepatology, 2017, 65( 3): 920- 928. DOI: 10.1002/hep.28932.
    [34] KURIHARA T, AKIMOTO M, ABE K, et al. Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia[J]. Clin Ther, 1993, 15( 5): 890- 898.
    [35] GU Y, YANG XQ, LIANG H, et al. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: A systematic review and meta-analysis[J]. BMC Gastroenterol, 2019, 19( 1): 231. DOI: 10.1186/s12876-019-1147-1.
    [36] SPELIOTES EK, BALAKRISHNAN M, FRIEDMAN LS, et al. Treatment of dyslipidemia in common liver diseases[J]. Clin Gastroenterol Hepatol, 2018, 16( 8): 1189- 1196. DOI: 10.1016/j.cgh.2018.04.023.
    [37] YAMAGUCHI M, ASANO T, ARISAKA T, et al. Effects of pemafibrate on primary biliary cholangitis with dyslipidemia[J]. Hepatol Res, 2022, 52( 6): 522- 531. DOI: 10.1111/hepr.13747.
    [38] DING DW, GUO GY, LIU YS, et al. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid[J]. Hepatol Commun, 2022, 6( 12): 3487- 3495. DOI: 10.1002/hep4.2103.
    [39] SHAPIRO MD, TAVORI H, FAZIO S. PCSK9: From basic science discoveries to clinical trials[J]. Circ Res, 2018, 122( 10): 1420- 1438. DOI: 10.1161/CIRCRESAHA.118.311227.
    [40] NISSEN SE, STROES E, DENT-ACOSTA RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial[J]. JAMA, 2016, 315( 15): 1580- 1590. DOI: 10.1001/jama.2016.3608.
    [41] HUR KY, MOON MK, PARK JS, et al. 2021 clinical practice guidelines for diabetes mellitus of the Korean diabetes association[J]. Diabetes Metab J, 2021, 45( 4): 461- 481. DOI: 10.4093/dmj.2021.0156.
    [42] GRUNDY SM, STONE NJ, BAILEY AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines[J]. Circulation. 2019, 139( 25): e1082- e1143. DOI: 10.1161/CIR.0000000000000625.
    [43] MACH F, BAIGENT C, CATAPANO AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk[J]. Eur Heart J, 2020, 41( 1): 111- 188. DOI: 10.1093/eurheartj/ehz455.
    [44] TUMMALA R, GUPTA M, DEVANABANDA AR, et al. Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis[J]. Ann Med, 2022, 54( 1): 1287- 1296. DOI: 10.1080/07853890.2022.2059559.
    [45] AGHA AM, JONES PH, BALLANTYNE CM, et al. Greater than expected reduction in low-density lipoprotein-cholesterol(LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia(HeFH)[J]. J Clin Lipidol, 2021, 15( 5): 649- 652. DOI: 10.1016/j.jacl.2021.07.002.
  • 加载中
计量
  • 文章访问数:  66
  • HTML全文浏览量:  20
  • PDF下载量:  26
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-05-04
  • 录用日期:  2023-05-26
  • 出版日期:  2024-01-23
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回